ClearPoint Neuro Inc. (CLPT) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CLPT scores 19 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 2 / 20 (ROIC -35%; FCF yield -7.13%), indicating the business is not currently generating returns on capital or positive free cash flow. The Whale 13F Flow pillar scores 5 / 20 for institutional accumulation and options positioning, the Insider Conviction pillar scores 3 / 20 for SEC Form 4 and Congressional PTR cluster flow, and the Macro Regime Fit pillar scores 3 / 20 (Beta 1.0; sector sensitivity). The Forensic Balance Sheet pillar scores 6 / 20 (Altman Z 0.2; Piotroski F 4/9; Debt/Equity 0.5), which is the weakest structural signal in the financial-distress assessment. For a prospective investor, the upside case rests on the reported gross margin of 61.4% and the revenue growth shown across FY 2023 to FY 2025, but the rating places more weight on negative operating economics, low Altman Z-Score reading, and weak insider and institutional support. Valuation tradeoffs cannot be assessed on earnings because P/E and EPS are not available in source data; the stock's positioning within its $8.27 - $24.75 52-week range and $342.7M market capitalization should be read against these forensic signals. This analysis is educational and not personalized financial advice.

Per the SEC financials, operating and net losses persisted across all three reported periods, with operating margin at -60% and net margin at -60% per the market data section. Gross margin is reported at 61.4%. ROIC is -35% per the market data section and the Roarable RQD rating. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9 per the Forensic Balance Sheet pillar. Debt/Equity is 0.5 per the same pillar, while debt values in the SEC financials are N/A.

• RISK WATCH (RED): A Yahoo Finance report headlined that CLPT reported a Q3 loss and missed revenue estimates.
• MARKET WIRE (YELLOW): A www.debelegger.nl report carried a general stock price and chart headline.
• CATALYST (GREEN): A GuruFocus report headlined revenue growth in Q3 and a reference to a gene-related item.
• MARKET WIRE (YELLOW): A Benzinga report carried the Q3 2026 earnings call transcript headline.
• RISK WATCH (RED): A Simply Wall St report headlined cash runway and loss pressure.
• RISK WATCH (RED): A Pluang report headlined a lawsuit probing CLPT over a stock drop following a Huntington's drug trial setback.

The Butterfly Supply-Chain Graph reports sector Health Care, industry Medical/Dental Instruments, supply chain NONE, with no butterfly links and no proprietary signals.

• What are the FY 2025 debt balances, given that debt is reported as N/A across all periods?
• What EPS, P/E, and EV/EBITDA figures apply, since these are not available in source data?
• What is the outcome of the lawsuit referenced in the Pluang report, and what is its potential financial exposure?
• What is the company's cash runway given the FY 2025 FCF of $-24.4M against $45.9M cash?
• What drove the FY 2025 revenue increase and does it reflect durable demand?